In the fall of 2019, Vertex launched Trikafta, the latest of its breakthrough therapies for people with cystic fibrosis. Capable of treating up to 90% of those who suffer from the progressive, life-threatening disease, the drug has already been used to treat thousands of patients in the U.S. and recently won approval in the EU. The company’s sales—$4.2 billion in 2019—have averaged 35% annual growth over the past three years. One setback: The biotech’s stock fell 23% in October after it scrapped a new drug in Phase II clinical trials.
- NewslettersVertex CEO takes an earnings victory lap right before he exitsJanuary 31, 2020 10:26 PM UTC
- NewslettersVertex’s $950 Million Bet on Stem Cells to Cure Diabetes: Brainstorm HealthSeptember 3, 2019 9:34 PM UTC
- HealthThis Biotech Just Gained Billions in Market Value Thanks to Its Cystic Fibrosis Drug CocktailJuly 19, 2017 8:15 PM UTC
- HealthThe FDA Wants Pharma to Ditch its Archaic Drug Making ProcessApril 14, 2016 8:52 PM UTC